Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 425 GBX -0.35% Market Closed
Market Cap: 450.2m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

Oxford BioMedica PLC
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Oxford BioMedica PLC
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Total Receivables
ÂŁ36.5m
CAGR 3-Years
-11%
CAGR 5-Years
1%
CAGR 10-Years
24%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Receivables
$39.1m
CAGR 3-Years
138%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Receivables
ÂŁ35.9m
CAGR 3-Years
77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Receivables
$58m
CAGR 3-Years
96%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Receivables
ÂŁ61.4m
CAGR 3-Years
54%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Receivables
ÂŁ137.3m
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
6%
No Stocks Found

Oxford BioMedica PLC
Glance View

Market Cap
447.5m GBX
Industry
Biotechnology

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
365.05 GBX
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Total Receivables?
Total Receivables
36.5m GBP

Based on the financial report for Jun 30, 2024, Oxford BioMedica PLC's Total Receivables amounts to 36.5m GBP.

What is Oxford BioMedica PLC's Total Receivables growth rate?
Total Receivables CAGR 10Y
24%

Over the last year, the Total Receivables growth was 24%. The average annual Total Receivables growth rates for Oxford BioMedica PLC have been -11% over the past three years , 1% over the past five years , and 24% over the past ten years .

Back to Top